Zobrazeno 1 - 10
of 64
pro vyhledávání: '"P. F. Geertsen"'
Autor:
Howard Gurney, Thomas Powles, Asim Amin, Bohuslav Melichar, Camillo Porta, David F McDermott, Toni K Choueiri, Marc-Oliver Grimm, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Hans J Hammers, Saby George, Robert J Motzer, Alain Ravaud, Osvaldo Arén Frontera, Frede Donskov, Philippe Barthélémy, Viktor Grünwald, Victoria Neiman, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Raya Leibowitz-Amit, Poul F Geertsen, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first
Externí odkaz:
https://doaj.org/article/633526ea5f4546a1a54c5f374b846edf
Autor:
M. van Overeem Felter, M. Josipovic, E. Serup-Hansen, P. F. Geertsen, C. F. Behrens, A. A. Khalil, G. F. Persson
Publikováno v:
Acta oncologica (Stockholm, Sweden). 61(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e2fd12b984de9cd2787a66387f04d9
https://pubmed.ncbi.nlm.nih.gov/36017569
https://pubmed.ncbi.nlm.nih.gov/36017569
Publikováno v:
Melanoma Research. 10:66-77
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bba8a4bdeb39bb09795035d53aae5a3
https://doi.org/10.1097/00008390-200010010-00009
https://doi.org/10.1097/00008390-200010010-00009
Publikováno v:
Clinical science (London, England : 1979). 95(1)
1. Renal haemodynamics, lithium and sodium clearance were measured in 14 patients treated with recombinant interleukin-2 for metastatic renal cell carcinoma. 2. Patients were studied before and after 72 h of continuous intravenous infusion of recombi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5200a08be336591c361020a0ad747122
https://pubmed.ncbi.nlm.nih.gov/9662488
https://pubmed.ncbi.nlm.nih.gov/9662488
Autor:
H, von der Maase, A, Osterlind, K T, Drzewiecki, K K, Dahlstrøm, P F, Geertsen, S B, Gjedde, N C, Hastrup, S B, Holmberg, C, Krag, J, Lock-Andersen
Publikováno v:
Ugeskrift for laeger. 154(28)
About 700 new cases of malignant melanoma of the skin are registered annually in Denmark. The incidence is increasing rapidly and the number of new cases increases by more than 5% per annum. The most important phenotypical risk factors are the number
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5e0f572fa7567e5cef0a63838400abee
https://pubmed.ncbi.nlm.nih.gov/1413219
https://pubmed.ncbi.nlm.nih.gov/1413219
Publikováno v:
Cancer research. 52(3)
The purpose of this study was to evaluate the efficacy of treatment with recombinant interleukin-2 (rIL-2) and lymphokine-activated killer cells in patients with advanced bladder cancer and to study the induced changes in the distribution of leukocyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0409a74a37521a60955097806900e263
https://pubmed.ncbi.nlm.nih.gov/1732060
https://pubmed.ncbi.nlm.nih.gov/1732060
Publikováno v:
Annals of the New York Academy of Sciences. 628
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac0ba3eb21c84cbb177c631cdc503396
https://pubmed.ncbi.nlm.nih.gov/2069314
https://pubmed.ncbi.nlm.nih.gov/2069314
Publikováno v:
The Journal of Urology. :2023-2024
Summary Background Approximately 5% of patients with testicular cancer harbour carcinoma in situ (CIS) in the contralateral testis. CIS will progress into invasive tumour in about 50% of cases within five years. The present study evaluated the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3cd82d960e6e14f59440e87fe7fd657
https://doi.org/10.1097/00005392-199906000-00090
https://doi.org/10.1097/00005392-199906000-00090
Publikováno v:
Ugeskrift for laeger. 152(47)
Interleukin-2 (IL-2) is produced by activated T-helper lymphocytes and stimulates both the antigen-specific and the non-specific immune defence. In vitro, IL-2 activated peripheral blood lymphocytes (LAK-cells) can lyse a broad spectrum of both NK-se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4871e71293674a079a2ca98c7b0bf43f
https://pubmed.ncbi.nlm.nih.gov/2256204
https://pubmed.ncbi.nlm.nih.gov/2256204
Autor:
Felter, M. van Overeem1, Josipovic, M.2,3, Serup-Hansen, E.1, Geertsen, P. F.1, Behrens, C. F.1,4, Khalil, A. A.5, Persson, G. F.1,3
Publikováno v:
Acta Oncologica. Sep2022, Vol. 61 Issue 9, p1148-1151. 4p. 1 Chart, 1 Graph.